| __timestamp | Amicus Therapeutics, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 79383000 |
| Thursday, January 1, 2015 | 47269000 | 108402000 |
| Friday, January 1, 2016 | 71151000 | 46928000 |
| Sunday, January 1, 2017 | 88671000 | 74959000 |
| Monday, January 1, 2018 | 127200000 | 79716000 |
| Tuesday, January 1, 2019 | 169861000 | 74669000 |
| Wednesday, January 1, 2020 | 156407000 | 59040000 |
| Friday, January 1, 2021 | 192710000 | 77417000 |
| Saturday, January 1, 2022 | 213041000 | 91473000 |
| Sunday, January 1, 2023 | 275270000 | 94314000 |
Unleashing the power of data
In the competitive world of biotechnology, managing expenses is crucial for survival and growth. Amicus Therapeutics, Inc. and MannKind Corporation, two prominent players in the industry, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Amicus Therapeutics has seen a staggering increase of over 1,200% in SG&A expenses, reflecting its aggressive expansion and investment in operational capabilities. In contrast, MannKind Corporation's SG&A expenses have remained relatively stable, with a modest increase of about 19% over the same period. This divergence highlights different strategic approaches: Amicus's focus on scaling operations versus MannKind's emphasis on maintaining cost efficiency. As the biotech landscape evolves, these financial strategies will play a pivotal role in shaping the future trajectories of these companies.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MannKind Corporation
SG&A Efficiency Analysis: Comparing Viatris Inc. and MannKind Corporation
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Dr. Reddy's Laboratories Limited and MannKind Corporation: SG&A Spending Patterns Compared
Bio-Techne Corporation or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Amicus Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of MorphoSys AG and Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
MannKind Corporation and Novavax, Inc.: SG&A Spending Patterns Compared